SCHEMBL3758475

SCHEMBL3758475

CN(CCc1ccccc1)C(=O)C1c2ccccc2C(=O)N1CCc1ccc(Cl)cc1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MDM2 Q00987 5/20 0.46
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
ALDH1A1 P00352 2/20 0.41
TP53 P04637 2/20 0.41
KCNA5 P22460 3/20 0.41
KCNH2 Q12809 2/20 0.41
SCN5A Q14524 1/20 0.41
SCN9A Q15858 1/20 0.41
GAA P10253 1/20 0.40
HTT P42858 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
KMT2A Q03164 1/20 0.40
P2RX7 Q99572 1/20 0.40
CACNA1G O43497 1/20 0.40
CACNA1H O95180 1/20 0.40
CACNA1I Q9P0X4 1/20 0.40
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3745658 0.92 PRMT5 (0.47) MDM2ALDH1A1TP53KCNA5KCNH2
SCHEMBL3748832 0.90 KCNA5 (0.46) MDM2NPC1RAB9AALDH1A1TP53
SCHEMBL3762651 0.84 MDM2 (0.46) MDM2TP53KCNA5KCNH2SCN5A
SCHEMBL3751140 0.84 MDM2 (0.44) MDM2ALDH1A1TP53KCNA5KCNH2
SCHEMBL3750835 0.83 MDM2 (0.57) MDM2RAB9AALDH1A1TP53KCNA5
SCHEMBL3754163 0.82 KCNA5 (0.44) MDM2ALDH1A1KCNA5KCNH2GAA
SCHEMBL3751721 0.81 P2RX7 (0.47) MDM2KCNA5KCNH2SCN5ASCN9A
SCHEMBL3753733 0.81 ALDH1A1 (0.62) MDM2ALDH1A1TP53KCNA5KCNH2
SCHEMBL3751622 0.79 SCN9A (0.62) KCNA5KCNH2SCN5ASCN9AP2RX7
SCHEMBL3750322 0.78 MDM2 (0.40) MDM2ALDH1A1TP53KCNA5KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias ASTRAZENECA AB (SE) 2010-11-25 US claimed
EP-2049484-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS AstraZeneca AB (SE) 2009-04-22 EP claimed
WO-2008008022-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS ASTRAZENECA AB (SE) 2008-01-17 WO claimed
US-20080015237-A1 NEW COMPOUNDS I/418 ASTRAZENECA AB (SE) 2008-01-17 US claimed
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias ASTRAZENECA AB (SE) 2010-11-25 US disclosed
EP-2049484-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS AstraZeneca AB (SE) 2009-04-22 EP disclosed
WO-2008008022-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS ASTRAZENECA AB (SE) 2008-01-17 WO disclosed
US-20080015237-A1 NEW COMPOUNDS I/418 ASTRAZENECA AB (SE) 2008-01-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015237-A1 NEW COMPOUNDS I/418 KCNH1, KCNH2, KCNH3 MDM2 3686/4885NPC1 790/4885RAB9A 483/4885
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias KCNH1, KCNH2, KCNQ2 MDM2 3351/4885NPC1 1060/4885RAB9A 899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.